The Association For Frontotemporal Degeneration

A notebook page with pens shows the text "Introduction to Frontotemporal Degeneration (FTD) 101" and "Rare Disease Day." The AFTD logo is at the top.

The image features a notepad graphic with a title "What is FTD?" A brain diagram highlights the frontal lobe in red and the temporal lobe in blue. Text below explains that Frontotemporal Degeneration (FTD) involves brain disorders affecting these regions. AFTD logo appears at the top, and "Rare Disease Day" text is at the bottom. A pen is illustrated to the left.

Illustrated notepad with the title "FTD Subtypes include:" at the top. Below are colored ovals labeled "Behavioral Variant FTD (bvFTD)," "Primary Progressive Aphasia (PPA)," "FTD-ALS," "Corticobasal Syndrome (CBS)," and "Progressive Supranuclear Palsy (PSP)." Descriptions of each include effects on personality, language, motor symptoms, movement, and balance. A red pen and AFTD logo are present. "Rare Disease Day" is noted at the bottom.

A notepad-style graphic with the AFTD logo at the top. Text reads: "FTD is frequently misdiagnosed as Alzheimer's, Depression, Parkinson's disease, or a psychiatric condition." Below, it explains that FTD has different symptoms and strikes younger. The bottom notes Rare Disease Day.

For Rare Disease Day, we’re flipping the page back to the basics of FTD.

FTD doesn’t always look the way people expect. It can change personality, language, or movement. It’s often mistaken for Alzheimer’s disease, depression, or a psychiatric condition.

Learn more: https://bit.ly/4aOwCpM

Since 2010, AFTD’s Education Conference has been a trusted space for education and connection — and it remains free for all attendees because of donor support.

❤️ Help us keep the 2026 Education Conference accessible to all. Give today: https://bit.ly/4aB8x6X

A person wearing a lab coat and glasses holds a tablet in a laboratory setting. Text reads: "Racing Toward Treatment: New Therapies Target the GRN Mutation." The "being patient" logo is shown.

About 20% of FTD cases are caused by single-gene variants — and roughly half of those involve GRN. Scientists are now exploring multiple approaches to raise progranulin levels, a key protein linked to this form of FTD.

Hope is on the horizon. Learn more: https://bit.ly/4qXeGiO

Webinar announcement for "Introduction to Frontotemporal Dementia (FTD) Biomarkers" on March 10, 2026, from 10:00-11:00 am ET. Organized by AFTD and the FTD Disorders Registry. Sponsored by AviadoBio. The speaker is Dr. Charlotte Teunissen, PhD, Professor of Neurochemistry at Amsterdam University Medical Center.

🧠 Biomarkers are changing how we understand FTD.

Learn what biomarkers are and how they’re advancing diagnosis and care. Join AFTD and the FTD Disorders Registry for a webinar on March 10 at 10 am ET with Dr. Charlotte Teunissen.

🔴 Sponsored by AviadoBio
👉 Register now: https://bit.ly/45RGKg5

In a cozy setting with brick walls, John Corvino is seated comfortably on a leather chair, holding a mug and smiling. Text on the image reads, "When Words Become Hard to Reach: John Corvino's Journey with PPAOS." The People magazine logo is also visible. Photo by Andrew Potter via people.com

Philosophy professor & public speaker John Corvino found he had Primary Progressive Apraxia of Speech, a rare FTD variant that’s particularly devastating for someone who makes his living through thoughtful, eloquent speaking.

➡️ Read his inspiring story: https://bit.ly/4tJ9cuI

Photo of the AFTD support group from Indiana meeting this January 2026 to celebrate their first year anniversary

AFTD's support group in Indiana celebrated its 1st anniversary, meeting every month since January '25. As members shared, even when “things are not perfect,” there is strength in having each other. Support groups offer understanding, shared experiences, and support. Join now: https://bit.ly/3ZC3L33

'AFTD Grantee Contributes to Study on Impact of Neuropsychiatric Symptoms in PSP' featuring a photo of Dr. Indira Garcia-Cordero

A study explores the impact of neuropsychiatric symptoms on the quality of life of people diagnosed with #PSP. Drs. Carmen Tartaglia and Indira Garcia-Cordero are among the co-authors.

➡️ Learn more: https://bit.ly/4tNdAZw

What makes the AFTD Education Conference so meaningful?

For Libba Adams, attending her first AFTD Education Conference meant connection, honesty, and feeling deeply understood alongside others who have experienced FTD.

Join us April 30–May 1 in Seattle or online: https://bit.ly/4tHoWOP

On February 15, The AFTD-Team laced up for the Austin Marathon and raised $17,243 in support of AFTD’s mission. ❤️

Every mile represented a commitment to the individuals and families facing FTD. We are deeply grateful to each runner, donor, and supporter who made this effort possible.

Webinar announcement for "Introduction to Frontotemporal Dementia (FTD) Biomarkers" on March 10, 2026, from 10:00-11:00 am ET. Organized by AFTD and the FTD Disorders Registry. Sponsored by AviadoBio. The speaker is Dr. Charlotte Teunissen, PhD, Professor of Neurochemistry at Amsterdam University Medical Center.

Learn how biomarkers help improve diagnosis, guide treatment, and advance research in FTD. Join AFTD, the FTD Disorders Registry, and Dr. Charlotte Teunissen for a free webinar on March 10 at 10 am ET that breaks it all down.

🔴 Sponsored by AviadoBio
👉 Register now: https://bit.ly/45RGKg5

Lessons Learned as a Person Diagnosed with FTD_1

Lessons Learned as a Person Diagnosed with FTD_2

Lessons Learned as a Person Diagnosed with FTD_3

These powerful suggestions come directly from AFTD’s Persons with FTD Advisory Council ❤️

These tips offer insight into what it means to live with FTD and how we can all support one another with compassion.

👉 Learn more: https://bit.ly/4ktUKTe

Photo and quote from Kay Webb for With Love 2026

This Valentine’s Day, we’re grateful to Kay Webb for sharing what love can look like in the face of FTD. ❤️

Through our 2026 With Love campaign, volunteers are helping ensure families have access to trusted information, resources, and community.

💌 Make a gift today: https://bit.ly/3NSLqMs

Did you know? 🧠

FTD is the most common form of young-onset dementia, often affecting people under 60. Because symptoms can impact behavior, language, or movement, FTD is frequently misunderstood, and receiving an accurate diagnosis can take years.

➡️ Learn more: https://bit.ly/4bUNqxP

Promotional graphic for a healthcare professional webinar titled 'Neurodegenerative Disease Biomarkers: What can they tell us about FTD?' hosted by AFTD, scheduled for Friday, February 13, 2026, from 12-1 p.m., with CME credit available. The image features the event details and three speaker photos with their names and titles: Howard Rosen, MD, Professor for Parkinsonian and Other Neurodegenerative Disorders at the Weill Institute for Neuroscience in UCSF’s Department of Neurology; Simon Ducharme, MD, FRCP, Neuropsychiatrist and a clinician-scientist at the Douglas Mental Health University Institute and the Montreal Neurological Institute; Sami Barmada, MD, PhD, Director of the Brain Bank and Associate Director of the Medical Scientist Training Program at the University of Michigan

New biomarkers are changing the way we understand dementia.

Join AFTD’s Healthcare Professional Webinar tomorrow at 12 p.m. ET, and three leading experts will unpack what these tools mean for earlier, more accurate FTD diagnoses.

🔴 Earn CME credit.
🔗 Register now: https://bit.ly/45v8N4C

Two individuals in lab coats are working in a laboratory setting. They are focused on documents. Nearby are laboratory equipment and shelves with various objects. The text on the image reads: "US FDA Accepts Investigational New Drug Application for Coya Therapeutics' Experimental Therapy for FTD." The Coya Therapeutics logo is displayed.

Coya Therapeutics announced that the US FDA accepted its investigational new drug (IND) application for its COYA 302 experimental therapy for FTD. The acceptance of the application will enable them to initiate clinical trials for the therapy in the U.S. Learn more: https://bit.ly/4anR0y3

Graphic with information on the FTD Diagnostic Biomarkers Initiative featuring award details and who can apply. Featuring logos from AFTD, Alzheimer's Association, Rainwater Charitable Foundation, and the Robertson Foundation.

The collaborative 2026 FTD Diagnostic Biomarkers Initiative funding opportunity is open now!

🏆 Awards are for up to two years and range from $250k-$700k.
📅 Letters of intent are due March 6.

🔴 For more information: https://bit.ly/4bWRJsb

Join the AFTD-Team Race Season and help bring awareness to families affected by FTD. Whether it’s a marathon, a 5K, or a bike tour, there’s a spot for you on our team in cities across the U.S. 🌍

📅 Races happening now through December 2026
➡️ Sign up and learn more: https://bit.ly/4qdVltz

'AFTD's Esther Kane and Volunteer Liz Zadnik Interviewed on Podcast' featuring a photo of a microphone and headset

AFTD's Esther Kane and Ambassador Liz Zadnik share expert guidance and personal experience on navigating FTD with hope and support on Friends Life Care.

🎙️ Listen to their powerful podcast conversation: https://bit.ly/3ZPraOk

Graphic for With Love 2026 featuring a photo and quote from AFTD Ambassador Melissa Fisher

Melissa F. honored her dad through With Love by transforming her grief into purpose by raising awareness and funds for FTD. Her story is a powerful reminder of why this campaign matters and how you can help make a difference for families facing FTD.

❤️ Support With Love today: https://bit.ly/3NSLqMs

'AARP Highlights What FTD Caregivers Need to Know' featuring Debra and Chris Tann (Left), photo by Audra Melton; (Right) Debra and Kevin Rhodes, photo by Jesse Burke. Photos via AARP.org

For FTD caregivers: It's changes in behavior & speech, not memory, that often come first. Learn what families need to know from AFTD experts, including AFTD Board chair Rita Choula.

👉 Read more: https://bit.ly/4kc8CkG

Promotional graphic for a healthcare professional webinar titled 'Neurodegenerative Disease Biomarkers: What can they tell us about FTD?' hosted by AFTD, scheduled for Friday, February 13, 2026, from 12-1 p.m., with CME credit available. The image features the event details and three speaker photos with their names and titles: Howard Rosen, MD, Professor for Parkinsonian and Other Neurodegenerative Disorders at the Weill Institute for Neuroscience in UCSF’s Department of Neurology; Simon Ducharme, MD, FRCP, Neuropsychiatrist and a clinician-scientist at the Douglas Mental Health University Institute and the Montreal Neurological Institute; Sami Barmada, MD, PhD, Director of the Brain Bank and Associate Director of the Medical Scientist Training Program at the University of Michigan

As dementia diagnostics evolve, more people are being diagnosed earlier. But what if it’s not Alzheimer’s?

Join AFTD’s Healthcare Professional Webinar on Feb. 13 to explore what emerging biomarker tools reveal about FTD and what they don’t.

🔴 Earn CME credit.
🔗 Register now: https://bit.ly/45v8N4C

Holloway Summit 2026 Group Photo

Thank you to the scientists, clinicians, and advocates who joined us for a vibrant, pragmatic discussion on how to improve diagnosis for FTD. Families deserve better!

Thank you to Kristin Holloway and the Holloway Family Fund for sharing your story and making the #HollowaySummit series possible!

Photo of the Holloway Summit 2026 featuring AFTD Ambassador Deb Scharper

AFTD Ambassador Deb Scharper contributes to the vibrant discussions on FTD diagnostics by adding perspective from an individual with lived experience of FTD.

Holloway Summit 2026 photo featuring AFTD's Holloway Scholars

These early-career researchers were recently selected as AFTD’s Holloway Scholars and invited to attend the #2026HollowaySummit due to their impactful work in FTD diagnostics.

Their travel was generously supported by the Holloway Family Fund – we are thankful for their continued commitment to FTD!

Recognizing that learning from related fields is crucial to progress, meeting attendees heard about the development and implementation of clinical guidelines from other neurological disorders. Dr. Dams-O'Connor spoke about clinical guidelines for brain injury and CTE.

Dr. Sterre de Boer speaks about the current state of FTD diagnostics, challenges faced, and provides a framework for the solution-based conversations that will arise over the next two meeting days.

Kristin Holloway kicked off the #2026HollowaySummit by sharing her inspirational story and explaining why progress in FTD diagnostics is so important.

Promotional image for AFTD featuring a person smiling at a laptop in a modern office setting, with text announcing 'AFTD is hiring Social Media Coordinator'. A prompt to visit their website for more details and application is included.

AFTD is hiring a Social Media Coordinator to help grow awareness, build community, and share resources for all impacted by FTD.

You’ll collaborate across teams, create content, and help drive the conversation forward.

💼 Portfolio required.
🔗 Apply today: https://bit.ly/4k16Frr

'The Lived Experience of FTD: FTD in the Arts' featuring photos of artwork from the event

When FTD enters a family, creativity can emerge in unexpected ways—both in those diagnosed and their loved ones.

🎨 Meet the artists transforming grief into beauty, finding solace in color, and proving that personhood endures through it all: https://bit.ly/4q2w6dp

Image of a support group featuring a quote from an anonymous person from the FTD support group

Caring for someone with FTD can feel isolating, but AFTD’s support groups create a space to connect, share, and feel seen. Whether you’re new to the journey or have been on it for years, you deserve support from people who understand.

❤️ Learn more and find a group near you: https://bit.ly/4qxDTBb